How Kohli was paid
$1.3M in total for 2026, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Incentive | Other | Total |
|---|---|---|---|---|---|
| Prashant KohliChief Executive Officer | $579,000 | $391,820 | $289,500 | $10,500 | $1,270,820 |
| Amresh KumarVice President, Program Management | $310,000 | $52,150 | $93,000 | $10,500 | $465,650 |
| Carrie D’AndreaFormer Vice President, Clinical Operations | $310,000 | $52,150 | $93,000 | $10,500 | $465,650 |
What changed and why
- $1.3M$1,270,820 CEO total compensation increased from $1,084,971 in fiscal 2025, primarily reflecting higher salary, options, and incentive compensation.
- 100%100% of target performance bonuses were awarded after the Company met corporate objectives tied principally to GTx-104 FDA review milestones.
- 50%50% CEO and 30% other NEO target bonuses were based on corporate objectives and capped at 100% of target.
- $2.08$2.08 was the exercise price for fiscal 2026 stock options, which vest quarterly over 36 months.
- June 5, 2026 marked Carrie D’Andrea’s employment cessation, although she received the same fiscal 2026 compensation as Amresh Kumar.
- 3%3% of salary is contributed to eligible employees’ 401(k) accounts under the safe-harbor provision.
Other Grace Therapeutics proxy statements
- 2025 proxy statement
Prashant Kohli paid $1.1M (+9% on the year).
Filed Jul 28, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.